Who Optimizes SG&A Costs Better? Novo Nordisk A/S or MorphoSys AG

Optimizing SG&A Costs: A Tale of Two Companies

In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Novo Nordisk A/S and MorphoSys AG, two giants in the industry, have shown contrasting strategies over the past decade. From 2014 to 2023, Novo Nordisk A/S consistently maintained higher SG&A expenses, peaking at approximately 61.6 billion in 2023, reflecting their expansive global operations. In contrast, MorphoSys AG, with a more focused approach, saw a significant rise in SG&A costs, reaching nearly 200 million in 2021, before stabilizing around 92 million in 2023. This 10-year trend highlights Novo Nordisk's robust market presence and MorphoSys's strategic cost management. As the industry evolves, these companies' ability to optimize SG&A expenses will be pivotal in maintaining their competitive edge.